Bristol-Myers Competitors

BMY -  USA Stock  

USD 68.15  0.58  0.84%

Bristol-Myers Squibb competes with Horizon Therapeutics; as well as few others. The company runs under Healthcare sector within Drug Manufacturers—General industry. Analyzing Bristol-Myers Squibb competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bristol-Myers Squibb to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bristol-Myers Squibb competition on your existing holdings. Continue to Bristol-Myers Squibb Correlation with its peers.

Search Competition 

 
Refresh
Return on Investment is likely to drop to -10.09 in 2021. Return on Average Assets is likely to drop to -0.07 in 2021. Bristol-Myers Squibb Total Assets are fairly stable at the moment as compared to the past year. Bristol-Myers Squibb reported Total Assets of 118.48 Billion in 2020. Assets Non Current is likely to rise to about 95.3 B in 2021, whereas Current Assets are likely to drop slightly above 25.8 B in 2021.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Bristol-Myers Squibb's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Bristol-Myers Squibb in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
67.2268.1569.08
Details
Intrinsic
Valuation
LowReal ValueHigh
61.3475.9576.88
Details
Naive
Forecast
LowNext ValueHigh
67.6468.5769.49
Details
14 Analysts
Consensus
LowTarget PriceHigh
62.0073.3080.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bristol-Myers Squibb. Your research has to be compared to or analyzed against Bristol-Myers Squibb's peers to derive any actionable benefits. When done correctly, Bristol-Myers Squibb's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Bristol-Myers Squibb.

Bristol-Myers Squibb Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bristol-Myers Squibb and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bristol-Myers and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bristol-Myers Squibb does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Bristol-Myers Squibb Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Bristol-Myers Squibb stock performing well and Bristol-Myers Squibb company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Bristol-Myers Squibb's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
TWTR
 1.68  0.08  0.03  0.11  3.04  0.031 (1.76)  3.38 (3.68)  15.16 
MSFT
 0.87  0.10  0.09  0.18  0.91  0.08 (1.00)  2.07 (1.62)  4.26 
UBER
 1.86 (0.37)  0.00 (0.90)  0.00 (0.16)  0.00  3.04 (4.17)  11.09 
F
 2.00  0.19  0.08  0.20  2.24  0.07 (2.32)  6.73 (2.86)  11.68 
T
 0.81 (0.16)  0.00 (0.16)  0.00 (0.14)  0.00  1.32 (2.07)  7.45 
A
 0.76  0.14  0.15  0.32  0.64  0.13 (0.88)  1.49 (1.35)  4.54 
CRM
 1.07  0.05  0.02  0.22  1.17  0.0149 (1.17)  2.74 (2.00)  7.43 
JPM
 1.02 (0.04) (0.02)  0.01  1.31 (0.019) (1.04)  2.01 (2.28)  6.45 
MRK
 0.84 (0.02)  0.00 (0.12)  0.00 (0.0452)  0.00  2.02 (1.79)  4.83 
XOM
 1.47  0.01  0.02  0.05  1.82  0.0174 (1.51)  3.22 (2.88)  7.08 

Cross Equities Net Income Analysis

Compare Bristol-Myers Squibb and related stocks such as Horizon Therapeutics Net Income Over Time
Select Fundamental

201020112012201320142015201620172018201920202021
HZNP
(27.1 M)(113.3 M)(87.8 M)(149 M)(263.6 M)39.5 M(165.6 M)(350.1 M)(38.4 M)573 M389.8 M420.6 M

Bristol-Myers Squibb and related stocks such as Horizon Therapeutics Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Bristol-Myers Squibb financial statement analysis. It represents the amount of money remaining after all of Bristol-Myers Squibb operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income to Non Controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Bristol-Myers Squibb Competitive Analysis

The better you understand Bristol-Myers Squibb competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bristol-Myers Squibb's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bristol-Myers Squibb's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BMY
HZNP
 0.84 
 68.15 
 0.11 
 102.61 
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Operating Margin
Current Valuation
Cash Flow from Operations
Retained Earnings
Current Asset
Five Year Return
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Price to Earnings To Growth
Current Liabilities
Total Asset
Short Ratio
Last Dividend Paid
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Day Typical Price
Accumulation Distribution
Daily Balance Of Power
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Bristol-Myers Squibb Competition Performance Charts

Complement your Bristol-Myers Squibb position

In addition to having Bristol-Myers Squibb in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Munis Thematic Idea Now

Munis
Munis Theme
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. Munis theme has 40 constituents.
View All  Next Launch Munis
Continue to Bristol-Myers Squibb Correlation with its peers. Note that the Bristol-Myers Squibb information on this page should be used as a complementary analysis to other Bristol-Myers Squibb's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Bristol-Myers Stock analysis

When running Bristol-Myers Squibb price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol-Myers that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol-Myers Squibb's value that differs from its market value or its book value, called intrinsic value, which is Bristol-Myers Squibb's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol-Myers Squibb's market value can be influenced by many factors that don't directly affect Bristol-Myers Squibb underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol-Myers Squibb's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol-Myers Squibb value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.